首页> 外文期刊>Infection and Drug Resistance >Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations
【24h】

Carbapenem-resistant Acinetobacter baumannii and Pseudomonas aeruginosa: characterization of carbapenemase genes and E-test evaluation of colistin-based combinations

机译:耐碳青霉烯的鲍曼不动杆菌和铜绿假单胞菌:碳青霉烯酶基因的表征和大肠杆菌素组合的E检验评估

获取原文
           

摘要

Background: Carbapenamase producing Acinetobacter baumannii and Pseudomonas aeruginosa are emerging worldwide limiting the use of carbapenems as effective and safe drugs. Purpose: To characterize different carbapenemase genes carried by carbapenem-resistant (CR) A. baumannii and P. aeruginosa isolates and to evaluate the in vitro effect of some colistin-based combinations by E-test method in Zagazig University Hospitals ICU isolates. Methods: CR A. baumannii and P. aeruginosa isolated from the surgical intensive care unit (ICU) were tested for carbapenemase genes by polymerase chain reaction and the effect of colistin/meropenem and colistin/tigecycline combinations was evaluated by E-test. Results: Genes coding for OXA-23, NDM and GES were detected in 90, 66.7 and 50% of CR A. baumannii , respectively, while genes coding for VIM, GES, NDM and IMP were detected in 50, 40.9, 27.3 and 18.2% of CR P. aeruginosa , respectively. Colistin/tigecycline combination showed synergistic and additive effect in 20% and 60% of A. baumannii isolates, respectively, while colistin/meropenem combination showed synergistic and additive effect in 63.6% and 36.4% of P. aeruginosa , respectively. Conclusion: Carbapenemase genes carriage accounts for high level carbapenem resistance in our isolates. Colistin/tigecycline and colistin/meropenem combinations can be considered for treatment of severe infections by CR A. baumannii and P. aeruginosa , respectively.
机译:背景:产生碳青霉烯酶的鲍曼不动杆菌和铜绿假单胞菌正在世界范围内出现,限制了碳青霉烯类作为有效和安全的药物的使用。目的:鉴定耐碳青霉烯(CR)的鲍曼不动杆菌和铜绿假单胞菌菌株携带的不同碳青霉烯酶基因,并通过E-test方法评估一些基于大肠菌素的组合在扎加济格大学医院ICU分离株中的体外作用。方法:通过聚合酶链反应检测从外科重症监护病房(ICU)分离的鲍氏不动杆菌和铜绿假单胞菌的碳青霉烯酶基因,并通过E检验评估大肠菌素/美罗培南和大肠菌素/替加环素组合的效果。结果:分别在90%,66.7%和50%的鲍曼不动杆菌中检测到编码OXA-23,NDM和GES的基因,而在50、40.9、27.3和18.2中检测到编码VIM,GES,NDM和IMP的基因。分别为CR铜绿假单胞菌的%。 Colistin / tigecycline组合分别对鲍曼不动杆菌的20%和60%表现出协同作用和加成作用,而colistin / meropenem组合对铜绿假单胞菌分别表现出协同作用和加成作用,分别为63.6%和36.4%。结论:碳青霉烯酶基因运输是我们分离株中高水平的碳青霉烯抗性的原因。共利斯汀/替加环素和粘菌素/美罗培南的组合可考虑分别用于治疗由鲍曼不动杆菌和铜绿假单胞菌引起的严重感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号